Amerikanische Gesellschaft für Hirudotherapie

Intravenous thrombolysis for acute cerebral embolism during atrial fibrillation ablation: a case report and systematic review with meta-analysis

Review published in Frontiers in cardiovascular medicine (2026)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienSicherheit & InfektionskontrolleCai B et al. · Frontiers in cardiovascular medicine, 2026

Abstract

INTRODUCTION: Periprocedural stroke represents a clinically important complication of atrial fibrillation ablation, and effective anticoagulation remains essential for risk reduction. However, the use of intravenous thrombolysis in patients with acute ischemic stroke who have recently received novel oral anticoagulants remains controversial under certain clinical circumstances. This report described an uncommon case of radiofrequency ablation-related ischemic stroke treated with intravenous thrombolysis after dabigatran reversal with idarucizumab. In parallel, we conducted a systematic review and meta-analysis to evaluate the safety and outcomes of this treatment strategy. METHODS: This study included analysis of an index case and a systematic review with meta-analysis. We report a 54-year-old patient who developed acute ischemic stroke shortly after radiofrequency catheter ablation for AF and was treated with intravenous thrombolysis after dabigatran reversal with idarucizumab. In parallel, a systematic literature search was conducted to identify observational studies, cohorts, and case series reporting idarucizumab-enabled thrombolysis in dabigatran-treated stroke patients. Data on intracranial hemorrhage (ICH), favorable functional outcome [modified Rankin Scale (mRS) 0-2], and mortality were extracted. Pooled estimates were calculated using random-effects meta-analysis of proportions, and comparative analyses with non-anticoagulated thrombolysis populations were performed using pooled risk ratios. RESULTS: Neuroimaging confirmed an acute cerebral infarction in the left thalamus. The patient had been receiving dabigatran and was treated with intravenous idarucizumab followed by intravenous alteplase. Neurological deficits rapidly improved after thrombolysis, and the patient achieved a favorable recovery over 90 days of follow-up. DISCUSSION: Findings from the systematic review and meta-analysis demonstrated low rates of intracranial hemorrhage, low mortality, and favorable functional outcomes comparable to standard thrombolysis populations. This case, together with accumulating evidence from the literature, supports the short-term safety and clinical effectiveness of idarucizumab-enabled intravenous thrombolysis in dabigatran-treated patients with periprocedural acute ischemic stroke. Therefore, early anticoagulant reversal followed by prompt reperfusion therapy may represent a feasible and safe therapeutic strategy in carefully selected patients.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Zusammenfassung

Periprocedural stroke represents a clinically important complication of atrial fibrillation ablation, and effective anticoagulation remains essential for risk reduction.

Warum dies für die Hirudotherapie relevant ist

This case report and systematic review with meta-analysis examined intravenous thrombolysis for acute ischemic stroke following atrial fibrillation ablation in dabigatran-treated patients, specifically after reversal with idarucizumab. A 54-year-old patient received idarucizumab followed by alteplase with rapid neurological improvement and favorable 90-day recovery, and pooled analysis suggested low intracranial hemorrhage rates, low mortality, and favorable functional outcomes comparable to standard thrombolysis populations. For ASH's domain, this work addresses anticoagulation reversal and reperfusion strategies—a conceptually adjacent area to leech-derived anticoagulants like hirudin—though no leech-derived agents were studied. The relevance to hirudotherapy is entirely indirect: the study involves pharmacological anticoagulation management and synthetic reversal agents, not leeches or the leech secretome.

Zitation

Intravenous thrombolysis for acute cerebral embolism during atrial fibrillation ablation: a case report and systematic review with meta-analysis

Cai B et al. · Frontiers in cardiovascular medicine, 2026

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.